849235-67-2

Basic information

• Product Name: Methyl 4-((4-(pyridin-3-yl)pyriMidin-2-ylaMino)Methyl)benzoate
• Synonyms: Methyl 4-((4-(pyridin-3-yl)pyriMidin-2-ylaMino)Methyl)benzoate;4-[[[4-(3-Pyridinyl)-2-pyrimidinyl]amino]methyl]benzoic acid methyl ester
• CAS NO: 849235-67-2
• Molecular Formula: C₁₈H₁₆N₄O₂
• Molecular Weight: 320.34524
• Mol File: 849235-67-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 4-((4-(pyridin-3-yl)pyriMidin-2-ylaMino)Methyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-((4-(pyridin-3-yl)pyriMidin-2-ylaMino)Methyl)benzoate(849235-67-2)
• EPA Substance Registry System: Methyl 4-((4-(pyridin-3-yl)pyriMidin-2-ylaMino)Methyl)benzoate(849235-67-2)

Safety Data

• Hazardous Substances Data: 849235-67-2(Hazardous Substances Data)

Upstream product

• 66521-66-2 4-pyridin-3-ylpyrimidin-2-ylamine 
• 1571-08-0 methyl 4-formylbenzoate 
• 55314-16-4 3-(N,N-dimethylamino)-1-(pyridin-3-yl)prop-2-en-1-one 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 736080-30-1 4-guanidinomethylbenzoic acid methyl ester 

Downstream Products

• 849235-68-3 4-(([4-(pyridin-3-yl)pyrimidin-2-yl]amino)methyl)benzoic acid 
• 726169-73-9 mocetinostat 
• 1448350-15-9 3-amino-4-[4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamido]benzoic acid 
• 1448350-14-8 benzyl 3-amino-4-[4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamido]benzoate 
• 1448350-20-6 benzyl 3-nitro-4-{[4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzene]amido}benzoate 
• 1448350-13-7 N-[2-amino-4-(hydroxymethyl)phenyl]-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide 
• 1448350-12-6 N-(2-amino-4-{[(tert-butyldimethylsilyl)oxy]methyl}phenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide 
• 1448350-19-3 N-(4-{[(tert-butyldimethylsilyl)oxy]methyl}-2-nitrophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide 
• 1448350-11-5 N-(2-amino-4-hydroxyphenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide 
• 1448350-10-4 N-(2-amino-4-methoxyphenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide 
• 1448350-09-1 N-(2-amino-4-bromophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide 
• 1448350-08-0 N-(2-amino-4-phenylphenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide 
• 1448350-17-1 N-(2-nitro-4-phenylphenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide 
• 1448350-07-9 N-(3-aminonaphthalen-2-yl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide 

Relevant articles and documents

Synthesis, Biological Activities and Docking Studies of Novel 4-(Arylaminomethyl)benzamide Derivatives as Potential Tyrosine Kinase Inhibitors

A number of new compounds containing the 4-(aminomethyl)benzamide fragment as a linker were designed and synthesized, and their biological activities were evaluated as potential anticancer agents. The cytotoxicity activity of the designed compounds was studied in two hematological and five solid cell lines in comparison with the reference drugs. Targeted structures against eight receptor tyrosine kinases including EGFR, HER-2, HER-4, IGF1R, InsR, KDR, PDGFRa, and PDGFRb were investigated. The majority of the compounds showed a potent inhibitory activity against the tested kinases. The analogues 11 and 13 with the (trifluoromethyl)benzene ring in the amide or amine moiety of the molecule were proven to be highly potent against EGFR, with 91% and 92% inhibition at 10 nM, respectively. The docking of synthesized target compounds for nine protein kinases contained in the Protein Data Bank (PDB) database was carried out. The molecular modeling results for analogue 10 showed that the use of the 4-(aminomethyl)benzamide as a flexible linker leads to a favorable overall geometry of the molecule, which allows one to bypass the bulk isoleucine residue and provides the necessary binding to the active center of the T315I-mutant Abl (PDB: 3QRJ).

Navigating into the chemical space between MGCD0103 and SAHA: Novel histone deacetylase inhibitors as a promising lead

Histone deacetylase inhibitors (HDIs) are an increasingly important class of cancer-targeting agents. Two kinds of small molecule histone deacetylase inhibitors, mainly employing the motifs of the two known HDAC inhibitors MGCD0103 and SAHA as the basic scaffolds, were designed, synthesized and evaluated for the preliminary biological activity. Strikingly, these two compounds regained a long half-life potency like MGCD0103 and retained the non-selectivity for HDAC1 versus HDAC6 derived from SAHA. Together, these two compounds combining both the advantages of MGCD0103 and SAHA could be considered as novel histone deacetylase inhibitors in targeted drug development and possibly anticipated to be more effective under the clinical trials.

Discovery of N-(2-Aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino) methyl]benzamide(MGCD0103), an orally active histone deacetylase inhibitor

The design, synthesis, and biological evaluation of N-(2-aminophenyl)-4- [(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide 8 (MGCD0103) is described. Compound 8 is an isotype-selective small molecule histone deacetylase (HDAC) inhibitor that selectively inhibits HDACs 1-3 and 11 at submicromolar concentrations in vitro. 8 blocks cancer cell proliferation and induces histone acetylation, p21ciP/waf1 protein expression, cell-cycle arrest, and apoptosis. 8 is orally bioavailable, has significant antitumor activity in vivo, has entered clinical trials, and shows promise as an anticancer drug.